120 related articles for article (PubMed ID: 1734946)
1. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
Albertini MR; Gibson DF; Robinson SP; Howard SP; Tans KJ; Lindstrom MJ; Robinson RR; Tormey DC; Jordan VC; Sondel PM
J Immunother (1991); 1992 Jan; 11(1):30-9. PubMed ID: 1734946
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
3. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
4. Modulation of lymphokine-activated killer cell-mediated cytotoxicity by estradiol and tamoxifen.
Baral E; Nagy E; Berczi I
Int J Cancer; 1996 Apr; 66(2):214-8. PubMed ID: 8603814
[TBL] [Abstract][Full Text] [Related]
5. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro.
Paulsen GH; Strickert T; Marthinsen AB; Lundgren S
Acta Oncol; 1996; 35(8):1011-9. PubMed ID: 9023387
[TBL] [Abstract][Full Text] [Related]
6. Interrelationship between estradiol and tamoxifen responses for clinical breast carcinoma cells cultured on contact-sensitive plates.
Matsuoka H; Nakamura Y; Ueo H; Sugimachi K; Tomoda H; Saito T; Seo Y
Jpn J Cancer Res; 1994 Jun; 85(6):619-25. PubMed ID: 8063615
[TBL] [Abstract][Full Text] [Related]
7. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
8. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
9. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
10. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
11. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
12. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells.
Charlier C; Chariot A; Antoine N; Merville MP; Gielen J; Castronovo V
Biochem Pharmacol; 1995 Jan; 49(3):351-8. PubMed ID: 7857322
[TBL] [Abstract][Full Text] [Related]
14. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
15. Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.
Jabrane-Ferrat N; Calvo F; Faille A; Lagabrielle JF; Boisson N; Quillet A; Fradelizi D
Br J Cancer; 1990 Apr; 61(4):558-62. PubMed ID: 2109997
[TBL] [Abstract][Full Text] [Related]
16. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
17. Modulation of target-cell culture conditions alters susceptibility to lymphocyte-mediated lysis.
Albertini MR; Howard SP; Fisch P; Lindstrom MJ; Hank JA; Gould MN; Sondel PM
J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):243-51. PubMed ID: 8334108
[TBL] [Abstract][Full Text] [Related]
18. Estrogen enhanced cell-cell signalling in breast cancer cells exposed to targeted irradiation.
Shao C; Folkard M; Held KD; Prise KM
BMC Cancer; 2008 Jun; 8():184. PubMed ID: 18590532
[TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
